Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors Steven Fruchtman - CEO, President & Director Mark Gelder - Chief Medical Officer Mark Guerin - CFO & COO Conference Call Participants Edouard Mullarky - Guggenheim Securities Ahu Demir - Ladenburg Thalmann & Co. Joseph Pantginis - H.C. Wainwright & Co. Robert LeBoyer - NOBLE Capital Markets Operator Ladies and gentlemen, thank you for standing by.

Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript

Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today

Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

NEWTOWN, Pa., March 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2023.

Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting

Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Data suggest rigosertib stimulates an anti-cancer immune response via NLRP3 activation, providing mechanistic support for clinical trials of rigosertib-checkpoint inhibitor combinations

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference

Two of two evaluable participants in an ongoing investigator-sponsored program of rigosertib in RDEB-associated squamous cell carcinoma (SCC) have achieved a complete response of all cancerous skin lesions

Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib's Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent members of the Company's Board of Directors.

Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

NEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the MedInvest Oncology Investor Conference being held in New York, NY on December 14-15, 2022.

Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference

NEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. Mark Guerin, Chief Operating Officer & Chief Financial Officer, will present a corporate overview at the conference on Tuesday, December 6th at 11:20 a.m. ET.

Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Dr. Steve Fruchtman - President & Chief Executive Officer Dr. Mark Gelder - Chief Medical Officer Mark Guerin - Chief Operating Officer & Chief Financial Officer Conference Call Participants Charles Zhu - Guggenheim Securities Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Capital Operator Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Third Quarter 2022 Financial Results and Business Update Conference Call.

Onconova Therapeutics, Inc. (ONTX) Q3 2022 Earnings Call Transcript

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -23.81% and 5%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Onconova Therapeutics, Inc. (ONTX) Reports Q3 Loss, Misses Revenue Estimates

Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; preliminary data expected 4Q23

Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, November 14, 2022 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, November 14, 2022

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022

NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in the Ladenburg Thalmann 2022 Healthcare Conference, which is taking place at the Sofitel Hotel in New York, NY.

Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

NEWTOWN, Pa., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced updated data from an investigator-sponsored Phase 1/2a trial of oral rigosertib plus the anti-PD-1 immune checkpoint inhibitor (ICI) nivolumab in advanced KRAS-mutated (KRAS+) non-small cell lung cancer (NSCLC). The data, which are featured in a poster at the European Society for Medical Oncology (ESMO) Congress 2022, show an early and encouraging signal of efficacy in the trial's extensively pre-treated population. The studied doublet has been well tolerated to-date.

Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022

NEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating virtually in the H.C. Wainwright 24th Annual Global Investment Conference, which is taking place in a hybrid format at the Lotte New York Palace Hotel.

Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Steve Fruchtman - President & Chief Executive Officer Mark Gelder - Chief Medical Officer Mark Guerin - Chief Operating Officer & Chief Financial Officer Conference Call Participants Charles Zhu - Guggenheim Chun Lung - Ladenburg Robert LeBoyer - Noble Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call.

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q2 2022 Results - Earnings Call Transcript

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates

Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022

Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022

Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer

Onconova Therapeutics Announces Key Management Promotions

In vitro and cell-based assays suggest narazaciclib's inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6 inhibitors In vitro and cell-based assays suggest narazaciclib's inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6 inhibitors

Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib's Differentiated Inhibitory and Improved Safety Profile in Preclinical Models

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Avi Oler - Senior Vice President-Corporate Development and General Counsel Steve Fruchtman - President and Chief Executive Officer Mark Gelder - Chief Medical Officer Mark Guerin - Chief Financial Officer Conference Call Participants Charles Zhu - Guggenheim Ahu Demir - Ladenburg Joe Pantginis - H.C. Wainright Robert LeBoyer - Noble Capital Markets Operator Ladies and gentlemen, thank you for standing by.

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q1 2022 Results - Earnings Call Transcript

Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the acceptance of an abstract for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting.

News for Onconova Therapeutics Stock (ONTX)